Related Experiment Videos
Intravenous MRI contrast enhancement of inflammatory synovium: a dose study
British Journal of Rheumatology
|December 1, 1996
Abstract:
A dose study was performed of MRI intravenous contrast medium enhancement of rheumatoid synovium in the knee, comparing the enhancement with gadoteridol at doses of 0.1 and 0.3 mmol/kg. A measurable and significant difference was demonstrated which has particular relevance to the accuracy of dose calculations needed when performing quantitative studies.
Insights
This study compared MRI contrast enhancement in rheumatoid knee synovium using two doses of gadoteridol. A significant difference in enhancement was found, impacting quantitative study dose accuracy.
Area of Science:
- Medical imaging
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) affects synovial joints, particularly the knee.
- Magnetic Resonance Imaging (MRI) is crucial for visualizing synovial inflammation in RA.
- Accurate contrast agent dosing is vital for quantitative MRI analysis.
Purpose of the Study:
- To evaluate the effect of different gadoteridol doses on MRI contrast enhancement in rheumatoid knee synovium.
- To determine the significance of dose-dependent enhancement for quantitative MRI studies in RA.
Main Methods:
- A dose-ranging study was conducted using MRI.
- Intravenous gadoteridol was administered at 0.1 mmol/kg and 0.3 mmol/kg.
- Synovial enhancement in the knee was measured and compared between the two doses.
Main Results:
- A measurable and statistically significant difference in synovial enhancement was observed between the 0.1 mmol/kg and 0.3 mmol/kg gadoteridol doses.
- The observed difference has implications for the precision of quantitative MRI assessments.
Conclusions:
- Gadoteridol dose significantly influences MRI contrast enhancement in rheumatoid knee synovium.
- Precise dose calculations are essential for accurate quantitative MRI studies in rheumatoid arthritis.